FDA to Share Postmarket Adverse Event Evaluations on New Website

Drug Industry Daily
A A
The FDA is making safety evaluations of postmarket adverse events publicly available on a new website and will update the information quarterly.

To View This Article:

Login

Subscribe To Drug Industry Daily